Solaris Asset Management’s Novartis NVS Stock Holding History

Solaris Asset Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-240	Closed	-$17K	–	374
2016 Q3	$17K	Buy	+240	New	+$17.5K	0.01%	246
2016 Q1	–	Sell	-15	Closed	-$1K	–	198
2015 Q4	$1K	Hold	15	–	–	﹤0.01%	181
2015 Q3	$1K	Buy	+15	New	+$1.33K	﹤0.01%	170

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MNA

Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return

Solaris Asset Management's NVS Position: Q4 2016 in Review

Solaris Asset Management sold out of Novartis (NVS) in Q4 2016, closing a stake of 240 shares — an estimated $17K sold.

Solaris Asset Management first reported a position in NVS in Q3 2015 and held it in 3 quarters. The position peaked at $17K in Q3 2016. 904 funds tracked by Wall St. Rank hold NVS as of Q4 2016.

Solaris Asset Management reported no remaining Novartis position as of Q4 2016 after selling out during the quarter.
Solaris Asset Management sold 240 Novartis shares in Q4 2016, an estimated $17K.
Solaris Asset Management first reported a position in Novartis in Q3 2015 and held it in 3 quarters.
Solaris Asset Management's Novartis position peaked at $17K in Q3 2016.
904 funds tracked by Wall St. Rank held Novartis as of Q4 2016.

Based on Solaris Asset Management's 13F filing for Q4 2016, filed 25 Jan 2017.